Immune checkpoints and rheumatic diseases: What can cancer immunotherapy teach us?

Nature Reviews Rheumatology

Volumn 12, Issue 10, 2016, Pages 593-604

  Van Der Vlist, Michiel ^a   Kuball, Jurgen ^a   Radstake, Timothy R D ^a   Meyaard, Linde ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IMMUNOMODULATING AGENT; INFLIXIMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; ANTIRHEUMATIC AGENT; PDCD1 PROTEIN, HUMAN;

ADVERSE DRUG REACTION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLADDER CANCER; CANCER IMMUNOTHERAPY; CELL SUBPOPULATION; CROHN DISEASE; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; HODGKIN DISEASE; HUMAN; HUMAN GENOME; HYPOPHYSITIS; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; KIDNEY CANCER; LIVER DISEASE; LUNG CANCER; MELANOMA; MYASTHENIA GRAVIS; NONHUMAN; ONCOLOGIST; ORGANIZING PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TARGET CELL; TISSUE SPECIFICITY; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; DRUG EFFECTS; EVIDENCE BASED MEDICINE; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; RHEUMATIC DISEASES; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; CELL CYCLE CHECKPOINTS; CTLA-4 ANTIGEN; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; INFLAMMATION; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; RHEUMATIC DISEASES; TREATMENT OUTCOME;

EID: 84983035733     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2016.131     Document Type: Review

References (129)

1. Medzhitov, R., Schneider, D. S., & Soares, M. P. Disease tolerance as a defense strategy. Science 335, 936-941 (2012).
2. Ravetch, J. V., & Lanier, L. L. Immune inhibitory receptors. Science 290, 84-89 (2000).
3. Daeron, M., Jaeger, S., Du Pasquier, L., & Vivier, E. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol. Rev. 224, 11-43 (2008).
4. Vivier, E., & Daeron, M. Immunoreceptor tyrosine-based inhibition motifs. Immunol. Today 18, 286-291 (1997).
5. Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. SHP 1 and SHP 2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173, 945-954 (2004).
6. Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD 1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141-151 (1999).
7. Olde Nordkamp, M. J., Koeleman, B. P., & Meyaard, L. Do inhibitory immune receptors play a role in the etiology of autoimmune disease? Clin. Immunol. 150, 31-42 (2014).
8. Couzin-Frankel, J. Breakthrough of the year 2013. Cancer immunotherapy. Science 342, 1432-1433 (2013).
9. Sharma, P., & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56-61 (2015).
10. Hanahan, D., & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
11. Postow, M. A., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006-2017 (2015).
12. Larkin, J., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
13. Parry, R. V., et al. CTLA 4 and PD 1 receptors inhibit T cell activation by distinct mechanisms. Mol. Cell. Biol. 25, 9543-9553 (2005).
14. Chambers, C. A., et al. The role of CTLA 4 in the regulation and initiation of T cell responses. Immunol. Rev. 153, 27-46 (1996).
15. Romano, E., et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc. Natl Acad. Sci. USA 112, 6140-6145 (2015).
16. Wherry, E. J., & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486-499 (2015).
17. Palucka, A. K., & Coussens, L. M. The basis of oncoimmunology. Cell 164, 1233-1247 (2016).
18. Michot, J. M., et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139-148 (2016).
19. US National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v.4. NIH, http://evs. nci.nih.gov/ftp1/CTCAE/About.html (2010).
20. Lacouture, M. E., et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J. Am. Acad. Dermatol. 71, 161-169 (2014).
21. Friedman, C. F., Proverbs-Singh, T. A., & Postow, M. A. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. http://dx.doi.org/10.1001/jamaoncol.2016.1051 (2016).
22. Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N. The "cancer immunogram". Science 352, 658-660 (2016).
23. Barjaktarevic, I. Z., Qadir, N., Suri, A., Santamauro, J. T., & Stover, D. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest 143, 858-861 (2013).
24. Antonia, S., et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 17, 299-308 (2016).
25. de Velasco, G., Bermas, B., & Choueiri, T. K. Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheumatol. 68, 556-557 (2016).
26. Cappelli, L. C., et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2016-209595 (2016).
27. Schadendorf, D., et al. Pooled analysis of long-Term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33, 1889-1894 (2015).
28. Zou, W., Wolchok, J. D., & Chen, L. PD L1 (B7 H1) and PD 1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv4 (2016).
29. Markle, J. G., & Fish, E. N. SeXX matters in immunity. Trends Immunol. 35, 97-104 (2014).
30. Tsokos, G. C. Systemic lupus erythematosus. N. Engl. J. Med. 365, 2110-2121 (2011).
31. Karnam, G., et al. CD200 receptor controls sex-specific TLR7 responses to viral infection. PLoS. Pathog. 8, e1002710 (2012).
32. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02671955 (2016).
33. Kyi, C., Carvajal, R. D., Wolchok, J. D., & Postow, M. A. Ipilimumab in patients with melanoma and autoimmune disease. J. Immunother. Cancer 2, 35 (2014).
34. Johnson, D. B., et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2, 234-240 (2015).
35. Pedersen, M., et al. Successful treatment with ipilimumab and interleukin 2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol. Immunother. 63, 1341-1346 (2014).
36. Bostwick, A. D., Salama, A. K., & Hanks, B. A. Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J. Immunother. Cancer 3, 19 (2015).
37. Liu, C., et al. Soluble PD 1 aggravates progression of collagen-induced arthritis through TH1 and TH17 pathways. Arthritis Res. Ther. 17, 340 (2015).
38. Lebbink, R. J., et al. The soluble leukocyte-Associated Ig like receptor (LAIR)-2 antagonizes the collagen/LAIR 1 inhibitory immune interaction. J. Immunol. 180, 1662-1669 (2008).
39. Ilan, N., & Madri, J. A. PECAM 1: old friend, new partners. Curr. Opin. Cell Biol. 15, 515-524 (2003).
40. Prokunina, L., et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet. 32, 666-669 (2002).
41. Fanciulli, M., et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat. Genet. 39, 721-723 (2007).
42. Barrett, J. C., et al. Genome-wide association study and meta-Analysis find that over 40 loci affect risk of type 1 diabetes. Nat. Genet. 41, 703-707 (2009).
43. Cooper, J. D., et al. Meta-Analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat. Genet. 40, 1399-1401 (2008).
44. Stahl, E. A., et al. Genome-wide association study meta-Analysis identifies seven new rheumatoid arthritis risk loci. Nat. Genet. 42, 508-514 (2010).
45. Plagnol, V., et al. Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases. PLoS. Genet. 7, e1002216 (2011).
46. Franke, A., et al. Genome-wide meta-Analysis increases to 71 the number of confirmed Crohn?s disease susceptibility loci. Nat. Genet. 42, 1118-1125 (2010).
47. Ceeraz, S., Nowak, E. C., Burns, C. M., & Noelle, R. J. Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. Arthritis Res. Ther. 16, 469 (2014).
48. van Gaalen, F., Ioan-Facsinay, A., Huizinga, T. W., & Toes, R. E. The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis. J. Immunol. 175, 5575-5580 (2005).
49. Nielen, M. M., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheumatol. 50, 380-386 (2004).
50. Gabrielli, A., Avvedimento, E. V., & Krieg, T. Scleroderma. N. Engl. J. Med. 360, 1989-2003 (2009).
51. Koenig, M., et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud?s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheumatol. 58, 3902-3912 (2008).
52. van Bon, L., Cossu, M., & Radstake, T. R. An update on an immune system that goes awry in systemic sclerosis. Curr. Opin. Rheumatol 23, 505-510 (2011).
53. Tarhini, A. A., et al. Baseline circulating IL 17 predicts toxicity while TGF b1 and IL 10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J. Immunother. Cancer 3, 39 (2015).
54. Lubberts, E. The IL 23-IL 17 axis in inflammatory arthritis. Nat. Rev. Rheumatol 11, 415-429 (2015).
55. van der Merwe, P. A., Bodian, D. L., Daenke, S., Linsley, P., & Davis, S. J. CD80 (B7 1) binds both CD28 and CTLA 4 with a low affinity and very fast kinetics. J. Exp. Med. 185, 393-403 (1997).
56. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00442611 (2015).
57. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02161406 (2015).
58. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00119678 (2014).
59. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00430677 (2016).
60. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00774852 (2016).
61. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02270957 (2015).
62. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00705367 (2013).
63. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02067910 (2015).
64. Mease, P., et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheumatol. 63, 939-948 (2011).
65. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01860976 (2016).
66. Yu, X., et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 10, 48-57 (2009).
67. Joller, N., et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J. Immunol. 186, 1338-1342 (2011).
68. Zhao, W., et al. TIGIT overexpression diminishes the function of CD4 T cells and ameliorates the severity of rheumatoid arthritis in mouse models. Exp. Cell Res. 340, 132-138 (2016).
69. Levin, S. D., et al. Vstm3 is a member of the CD28 family and an important modulator of T cell function. Eur. J. Immunol. 41, 902-915 (2011).
70. Wang, L., et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 208, 577-592 (2011).
71. Wang, L., et al. Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. Proc. Natl Acad. Sci. USA 111, 14846-14851 (2014).
72. Ceeraz, S., Sergent, P., Schned, A., Burns, C., & Noelle, R. J. Therapeutic role of the novel checkpoint regulator VISTA in murine autoimmune disease models. (P5174). J. Immunol. 190 (Suppl. 1), 194.4 (2013).
73. Merrill, J. T., et al. The efficacy and safety of abatacept in patients with non-life-Threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 62, 3077-3087 (2010).
74. Furie, R., et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 66, 379-389 (2014).
75. Bolland, S., & Ravetch, J. V. Spontaneous autoimmune disease in Fc?RIIB-deficient mice results from strain-specific epistasis. Immunity 13, 277-285 (2000).
76. Yuasa, T., et al. Deletion of Fc? receptor IIB renders H-2b mice susceptible to collagen-induced arthritis. J. Exp. Med. 189, 187-194 (1999).
77. Veri, M. C., et al. Therapeutic control of B cell activation via recruitment of Fc? receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheumatol. 62, 1933-1943 (2010).
78. Horton, H. M., et al. Antibody-mediated coengagement of Fc?RIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J. Immunol. 186, 4223-4233 (2011).
79. Tada, Y., et al. Acceleration of the onset of collagen-induced arthritis by a deficiency of platelet endothelial cell adhesion molecule 1. Arthritis Rheumatol. 48, 3280-3290 (2003).
80. Wong, M. X., Hayball, J. D., Hogarth, P. M., & Jackson, D. E. The inhibitory co receptor, PECAM 1 provides a protective effect in suppression of collagen-induced arthritis. J. Clin. Immunol. 25, 19-28 (2005).
81. Fornasa, G., et al. TCR stimulation drives cleavage and shedding of the ITIM receptor CD31. J. Immunol. 184, 5485-5492 (2010).
82. Clement, M., et al. Upholding the T cell immune-regulatory function of CD31 inhibits the formation of T/B immunological synapses in vitro and attenuates the development of experimental autoimmune arthritis in vivo. J. Autoimmun. 56, 23-33 (2015).
83. Muller, J., & Nitschke, L. The role of CD22 and Siglec G in B cell tolerance and autoimmune disease. Nat. Rev. Rheumatol. 10, 422-428 (2014).
84. Fleischer, V., et al. Epratuzumab inhibits the production of the proinflammatory cytokines IL 6 and TNFa, but not the regulatory cytokine IL 10, by B cells from healthy donors and SLE patients. Arthritis Res. Ther. 17, 185 (2015).
85. Sieger, N., et al. CD22 ligation inhibits downstream B cell receptor signaling and Ca2+ flux upon activation. Arthritis Rheumatol. 65, 770-779 (2013).
86. Wallace, D. J., et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow up. Rheumatology (Oxford) 52, 1313-1322 (2013).
87. Wallace, D. J., et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann. Rheum. Dis. 73, 183-190 (2014).
88. Strand, V., et al. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford) 53, 502-511 (2014).
89. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01262365 (2016).
90. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01261793 (2016).
91. Rossi, E. A., et al. Trogocytosis of multiple B cell surface markers by CD22 targeting with epratuzumab. Blood 122, 3020-3029 (2013).
92. Bennett, L., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711-723 (2003).
93. Tan, F. K., et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 45, 694-702 (2006).
94. Wildenberg, M. E., van Helden-Meeuwsen, C. G., van de Merwe, J. P., Drexhage, H. A., & Versnel, M. A. Systemic increase in type I interferon activity in Sjogren?s syndrome: a putative role for plasmacytoid dendritic cells. Eur. J. Immunol. 38, 2024-2033 (2008).
95. Kalunian, K. C., et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-A) in patients with systemic lupus erythematosus (ROSE). Ann. Rheum. Dis. 75, 196-202 (2016).
96. Pellerin, A., et al. Anti BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc dependent and Fc independent mechanisms. EMBO Mol. Med. 7, 464-476 (2015).
97. Brinkmann, V., et al. Neutrophil extracellular traps kill bacteria. Science 303, 1532-1535 (2004).
98. Lood, C., et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat. Med. 22, 146-153 (2016).
99. Corsiero, E., et al. Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs. Ann. Rheum. Dis. http://dx.doi. org/10.1136/annrheumdis-2015-208356 (2015).
100. Knight, J. S., et al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann. Rheum. Dis. 74, 2199-2206 (2015).
101. Mousseau, D. D., Banville, D., L?Abbe, D., Bouchard, P., & Shen, S. H. PILRa, a novel immunoreceptor tyrosine-based inhibitory motif-bearing protein, recruits SHP 1 upon tyrosine phosphorylation and is paired with the truncated counterpart PILRb. J. Biol. Chem. 275, 4467-4474 (2000).
102. Steevels, T. A. M., Lebbink, R. J., Westerlaken, G. H. A., Coffer, P. J., & Meyaard, L. Signal inhibitory receptor on leukocytes 1 (SIRL 1) is a novel functional inhibitory immune receptor expressed on human phagocytes. J. Immunol. 184, 4741-4748 (2010).
103. Van Avondt, K., Fritsch-Stork, R., Derksen, R. H., & Meyaard, L. Ligation of signal inhibitory receptor on leukocytes 1 suppresses the release of neutrophil extracellular traps in systemic lupus erythematosus. PLoS ONE 8, e78459 (2013).
104. Wang, J., Shiratori, I., Uehori, J., Ikawa, M., & Arase, H. Neutrophil infiltration during inflammation is regulated by PILRa via modulation of integrin activation. Nat. Immunol. 14, 34-40 (2013).
105. Sun, Y., et al. PILRa negatively regulates mouse inflammatory arthritis. J. Immunol. 193, 860-870 (2014).
106. Wright, G. J., et al. Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity 13, 233-242 (2000).
107. Wright, G. J., et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J. Immunol. 171, 3034-3046 (2003).
108. Rijkers, E. S. K., et al. The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes. Mol. Immunol. 45, 1126-1135 (2008).
109. Rygiel, T. P., & Meyaard, L. CD200R signaling in tumor tolerance and inflammation: a tricky balance. Curr. Opin. Immunol. 24, 233-238 (2012).
110. Mukhopadhyay, S., et al. Immune inhibitory ligand CD200 induction by TLRs and NLRs limits macrophage activation to protect the host from meningococcal septicemia. Cell Host. Microbe 8, 236-247 (2010).
111. Simelyte, E., Alzabin, S., Boudakov, I., & Williams, R. CD200R1 regulates the severity of arthritis but has minimal impact on the adaptive immune response. Clin. Exp. Immunol. 162, 163-168 (2010).
112. Copland, D. A., et al. Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. Am. J. Pathol. 171, 580-588 (2007).
113. Liu, Y., et al. CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis. J. Neurosci. 30, 2025-2038 (2010).
114. Simelyte, E., et al. CD200 Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis. Arthritis Rheumatol. 58, 1038-1043 (2008).
115. Varin, A., Pontikoglou, C., Labat, E., Deschaseaux, F., & Sensebe, L. CD200R/CD200 inhibits osteoclastogenesis: new mechanism of osteoclast control by mesenchymal stem cells in human. PLoS ONE 8, e72831 (2013).
116. Lee, L., Liu, J., Manuel, J., & Gorczynski, R. M. A role for the immunomodulatory molecules CD200 and CD200R in regulating bone formation. Immunol. Lett. 105, 150-158 (2006).
117. Ren, Y., et al. Aberrant CD200/CD200R1 expression and its potential role in TH17 cell differentiation, chemotaxis and osteoclastogenesis in rheumatoid arthritis. Rheumatology (Oxford) 54, 712-721 (2015).
118. Kurlander, R. J. Blockade of Fc receptor-mediated binding to U-937 cells by murine monoclonal antibodies directed against a variety of surface antigens. J. Immunol. 131, 140-147 (1983).
119. Shibayama, S., Imai, M., Shimbo, T., Tezuka, T., & Nakano, Y. A novel therapeutic approach for autoimmunity: PD 1 agonist. ECI Vienna http://www. eci-vienna2015.org/images/docs/ECI2015-Poster-Sessions.pdf (2015).
120. Suntharalingam, G., et al. Cytokine storm in a phase 1 trial of the anti CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
121. Vafa, O., et al. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 65, 114-126 (2014).
122. Brezski, R. J., & Georgiou, G. Immunoglobulin isotype knowledge and application to Fc engineering. Curr. Opin. Immunol. 40, 62-69 (2016).
123. Finck, B. K., Linsley, P. S., & Wofsy, D. Treatment of murine lupus with CTLA4Ig. Science 265, 1225-1227 (1994).
124. Newman, P. J. Switched at birth: a new family for PECAM 1. J. Clin. Invest. 103, 5-9 (1999).
125. Dunussi-Joannopoulos, K., et al. B Cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model. Blood 106 2235-2243 2005).
126. Fournier, N., et al. FDF03, a novel inhibitory receptor of the immunoglobulin superfamily, is expressed by human dendritic and myeloid cells. J. Immunol. 165, 1197-1209 (2000).
127. Boruchov, A. M., et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115, 2914-2923 (2005).
128. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02376036 (2016).
129. Agata, Y., et al. Expression of the PD 1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765-772 (1996).